Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q20706966> ?p ?o }
Showing triples 1 to 23 of
23
with 100 triples per page.
- Q20706966 subject Q9134654.
- Q20706966 abstract "LY-2940094 is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder and alcohol dependence. It has demonstrated proof-of-concept clinical efficacy for depression. As of 2015, it is in phase II clinical trials for both of the aforementioned indications. Its chemical structure has yet to be published.".
- Q20706966 wikiPageExternalLink 800033400.
- Q20706966 wikiPageWikiLink Q12745583.
- Q20706966 wikiPageWikiLink Q14911984.
- Q20706966 wikiPageWikiLink Q285166.
- Q20706966 wikiPageWikiLink Q30612.
- Q20706966 wikiPageWikiLink Q410943.
- Q20706966 wikiPageWikiLink Q42844.
- Q20706966 wikiPageWikiLink Q4713263.
- Q20706966 wikiPageWikiLink Q500256.
- Q20706966 wikiPageWikiLink Q6109058.
- Q20706966 wikiPageWikiLink Q632240.
- Q20706966 wikiPageWikiLink Q7180990.
- Q20706966 wikiPageWikiLink Q7388915.
- Q20706966 wikiPageWikiLink Q9134654.
- Q20706966 type ChemicalSubstance.
- Q20706966 type Drug.
- Q20706966 type ChemicalObject.
- Q20706966 type Thing.
- Q20706966 type Q8386.
- Q20706966 comment "LY-2940094 is a potent and selective nociceptin receptor antagonist which is under investigation by Eli Lilly for the treatment of major depressive disorder and alcohol dependence. It has demonstrated proof-of-concept clinical efficacy for depression. As of 2015, it is in phase II clinical trials for both of the aforementioned indications. Its chemical structure has yet to be published.".
- Q20706966 label "LY-2940094".